|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
GB8909916D0
(en)
*
|
1989-04-29 |
1989-06-14 |
Delta Biotechnology Ltd |
Polypeptides
|
|
US20040175795A1
(en)
|
1991-09-20 |
2004-09-09 |
Amgen Inc. |
Glial derived neurotrophic factor
|
|
ATE275197T1
(de)
|
1991-09-20 |
2004-09-15 |
Amgen Inc |
Glial neurotrophe faktor
|
|
US5733875A
(en)
|
1994-11-15 |
1998-03-31 |
Amgen Inc. |
Methods of using GDNF as a neuroprotective agent
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AU5576796A
(en)
|
1995-04-26 |
1996-11-18 |
Regeneron Pharmaceuticals, Inc. |
Methods of using neurotrophic factors to enhance neuronal gr afts
|
|
US6184200B1
(en)
|
1995-09-28 |
2001-02-06 |
Amgen Inc. |
Truncated glial cell line-derived neurotrophic factor
|
|
US5731284A
(en)
|
1995-09-28 |
1998-03-24 |
Amgen Inc. |
Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
|
|
US5641749A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
|
|
AU1121997A
(en)
|
1995-11-29 |
1997-06-19 |
Amgen, Inc. |
Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
|
|
US5641750A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5837681A
(en)
|
1996-02-23 |
1998-11-17 |
Amgen Inc. |
Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5929041A
(en)
|
1996-02-23 |
1999-07-27 |
Amgen Inc. |
Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US6455277B1
(en)
|
1996-04-22 |
2002-09-24 |
Amgen Inc. |
Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
|
|
US7138251B1
(en)
|
1996-04-22 |
2006-11-21 |
Amgen Inc. |
Polynucleotides encoding a neurotrophic factor receptor
|
|
JP2002505576A
(ja)
|
1997-05-30 |
2002-02-19 |
アムジエン・インコーポレーテツド |
神経栄養因子レセプター
|
|
AU2354600A
(en)
|
1998-12-09 |
2000-06-26 |
Amgen, Inc. |
Grnf4 a neurotrophic factor
|
|
US7160924B2
(en)
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
DE60041564D1
(de)
|
1999-12-24 |
2009-03-26 |
Genentech Inc |
Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
|
|
EP1594530A4
(en)
*
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
|
US8946151B2
(en)
|
2003-02-24 |
2015-02-03 |
Northern Bristol N.H.S. Trust Frenchay Hospital |
Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
|
|
BRPI0511755A
(pt)
*
|
2004-06-01 |
2008-01-02 |
Domantis Ltd |
composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
|
|
WO2006031994A2
(en)
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
|
US8008453B2
(en)
*
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8497246B2
(en)
*
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
|
ES2415604T3
(es)
*
|
2007-05-30 |
2013-07-26 |
Postech Academy-Industry- Foundation |
Proteínas de fusión de inmunoglobulina
|
|
WO2008145139A1
(en)
*
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
WO2009070597A2
(en)
*
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
AU2010258052A1
(en)
*
|
2009-06-11 |
2012-01-12 |
Angiochem Inc. |
Fusion proteins for delivery of GDNF and BDNF to the central nervous system
|
|
JP2013511281A
(ja)
|
2009-11-23 |
2013-04-04 |
アムジェン インコーポレイテッド |
単量体抗体Ｆｃ
|
|
US9469676B2
(en)
|
2011-04-13 |
2016-10-18 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
US20160296632A1
(en)
*
|
2013-11-13 |
2016-10-13 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
|
ES2913840T3
(es)
|
2014-03-20 |
2022-06-06 |
Bristol Myers Squibb Co |
Dominios de tipo III de fibronectina de unión a seroalbúmina
|
|
WO2018089702A1
(en)
|
2016-11-10 |
2018-05-17 |
Keros Therapeutics, Inc. |
Gdnf fusion polypeptides and methods of use thereof
|